Johnson & Johnson's Ebola vaccine program safely induces strong immune responses in healthy and HIV adults

Recently, data from a study published in the journal PLOS Medicine in the United States showed that Johnson & Johnson (JNJ)'s Ebola vaccine program (2-dose immunization)-Zabdeno® (Ad26.

Johnson & Johnson's Ebola vaccine program (Zabdeno®+Mvabea®) received marketing authorization from the European Commission (EC) in July 2020, and was prequalified by the World Health Organization (WHO) in April 2021

Since the outbreak of the West Africa epidemic in 2014, with the power of global public-private cooperation, Johnson & Johnson's Ebola vaccine program (Zabdeno®+Mvabea®) obtained regulatory approval in less than 6 years

The data published in the journal PLOS Medicine come from the second phase of the EBL2002 study

Since the Ebola virus was discovered in 1976, more than 30 outbreaks have been announced, the most serious of which has occurred in Africa in the past seven years

Johnson & Johnson responded to the recent Ebola epidemic by providing vaccine programs to governments and the World Health Organization (WHO)

Note: The original text has been deleted

Original source: Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV